<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02001272</url>
  </required_header>
  <id_info>
    <org_study_id>2012-772</org_study_id>
    <nct_id>NCT02001272</nct_id>
  </id_info>
  <brief_title>EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer</brief_title>
  <acronym>EWOC-1</acronym>
  <official_title>EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard of first-line chemotherapy in advanced ovarian cancer is the combination
      of carboplatin AUC 5mg/mL/min and paclitaxel 175 mg.m-². This combination is feasible in
      selected elderly patients such as those included in prospective trials. These trials,
      however, include a minority of the elderly population. In wider selection of patients &gt;70
      years old, the standard carboplatin-paclitaxel regimen has been shown to induce an excess of
      toxicity and premature treatment stopping. For elderly patients thought to be vulnerable and
      at high risk of toxicity with the standard 3-weekly carboplatin-paclitaxel regimen, other
      options are used in routine practice. One option is to delete paclitaxel and treat elderly
      patients with carboplatin as a single agent. An alternative is to use the
      carboplatin-paclitaxel regimen in a weekly schedule for both drugs such as reported by the
      MITO (Multicentre Italian Trial in Ovarian Cancer).

      To date, there is no randomized trial which could give us some evidence of how to select
      patients who could benefit most of one or the other regimen described above. The 4th Ovarian
      Cancer Consensus Conference has indeed recognised the medical unmet need of adapted therapy
      for elderly patients with ovarian cancer and the necessity of additional research in this
      population.

      Recently, GINECO has described a Geriatric Vulnerability Score (GVS) in a population of
      elderly patients with advanced ovarian cancer included in a specific multicenter phase II
      trial. The best proportional hazard model fitting for overall survival identified the
      following geriatric covariates score as being poor survival risk factors: ADL score &lt;6, IADL
      score &lt;25, HADS score &gt;14, albuminemia &lt;35g/L and , lymphopenia &lt;1G/L. GVS is the sum of
      these risk factors for each patient. Using a cut off of 3, the GVS identified a group of
      patients at high risk of severe toxicity, early cessation of treatment, unplanned
      hospitalization and adverse outcomes.

      This international multicentre randomized phase II trial will compare the success rate of
      delivering 6 courses of chemotherapy with evidence of efficacy and without premature
      termination for progression, death or unacceptable toxicity of three different chemotherapy
      regimens in a selected population of elderly patients with a GVS ≥ 3:

        -  Arm A: Paclitaxel 175mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks

        -  Arm B: Carboplatin monotherapy AUC 5 or 6 every 3 weeks

        -  Arm C: Weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 every
           4 weeks)

      The total number of patients to be enrolled is 240, ie 22 in each arm (total = 66) at the
      first step, then 58 more by arm (total=174) after interim analysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success.Treatment success is defined as the ability to deliver 6 courses of chemotherapy without premature termination for progression, death or unacceptable toxicity</measure>
    <time_frame>After 6 courses of chemotherapy i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Treatment success is defined as the ability to deliver 6 courses of chemotherapy without premature termination for progression, death or unacceptable toxicity. Unacceptable toxicity is defined as a major adverse event related to chemotherapy or treatment procedure leading either to early treatment stopping, to an unplanned hospital admission or to death or to a dose delay lasting more than 14 days or more than 2 dose reductions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutical strategy</measure>
    <time_frame>At the end of treatment (6 courses ), i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Therapeutical strategy will be assessed by measuring the feasibility of performing an optimal surgery and feasibility of performing neoadjuvant chemotherapy and surgery and post operative chemotherapy until 6 courses in case of planned interval debulking surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2.5 years</time_frame>
    <description>Overall survival is defined as the time period from the date of randomization to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2.5 years</time_frame>
    <description>Progression-free survival is defined as the time period from the date of randomization to the date of disease progression or death whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>At the end of treatment (6 courses ), i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Quality of life is evaluated using the FACT-O questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>At the end of treatment (6 courses ), i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Adverse events are defined using the NCI-CTC AE scale version 4.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aging biomarkers</measure>
    <time_frame>At the end of treatment (6 courses ), i.e 4.5 to 6 months (depending on the arm)</time_frame>
    <description>Aging biomarkers are represented by the expression level of cathelin-related antimicrobial peptide or CRAMP, stathmin, EF-1α, and chitinase</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>A:Paclitaxel + Carboplatin every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the arm A receive 6 courses the following regimen: Paclitaxel 175 mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks (1 cycle = 21 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B:Carboplatin monotherapy every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the arm B receive 6 courses the following regimen: Carboplatin monotherapy AUC 5 or 6 every 3 weeks (1 cycle = 21 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C:Weekly Paclitaxel and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the arm C receive 6 courses the following regimen: weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 ; d1=d29) (1 cycle = 28 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Carboplatin every 3 weeks</intervention_name>
    <description>Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.</description>
    <arm_group_label>A:Paclitaxel + Carboplatin every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin monotherapy every 3 weeks</intervention_name>
    <description>A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.</description>
    <arm_group_label>B:Carboplatin monotherapy every 3 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Weekly Paclitaxel and Carboplatin</intervention_name>
    <description>A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.</description>
    <arm_group_label>C:Weekly Paclitaxel and Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman &gt;70 year old

          -  Histologically or cytologically proven FIGO stage III to IV epithelial ovarian cancer
             or peritoneal primary or fallopian tube. A cytological proof is accepted if associated
             with a ratio of CA125/CEA &gt;25 and a radiological pelvic mass.

          -  GVS (Geriatric Vulnerability Score) &gt;3.

          -  Adequate bone marrow function including the following: Neutrophils ≥ 1.5 x 109/L ,
             platelets ≥100 x 109/L and hemoglobin ≥9 g/dL.

          -  Adequate glomerular filtration rate &gt;40 ml/min (estimates based on MDRD or Chatelut
             formula are sufficient)

          -  No icterus.

          -  Life expectancy &gt; 3 months.

          -  Written informed consent obtained.

          -  Covered by a Health System where applicable

        Exclusion Criteria:

          -  Other malignancy within the last 5 years, except for adequately treated carcinoma in
             situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited
             basal cell skin cancer.

          -  Prior history of chemotherapy.

          -  Prior history of radiotherapy which may affect patient tolerability to chemotherapy.

          -  Major perturbations of liver biology: Bilirubin &gt; 2 fold the upper normal limit (UNL),
             SGOT-SGPT &gt; 3 fold UNL.

          -  Patient unable to be regularly followed for any reason (geographic, familial, social,
             psychologic).

          -  Any mental or physical handicap at risk of interfering with the appropriate treatment.

          -  Known allergy to Cremophor ® EL -containing drugs.

          -  Any administrative or legal supervision where applicable
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire FALANDRY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'oncogériatrie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire FALANDRY, MD</last_name>
    <phone>4 78 86 15 80</phone>
    <phone_ext>+33</phone_ext>
    <email>claire.falandry@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie LE FUR</last_name>
    <phone>1 42 34 83 23</phone>
    <phone_ext>+33</phone_ext>
    <email>nlefur@arcagy.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Notre-Dame Hospital of the CHUM</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas WARKUS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulla PEEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marja KOMULAINEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier d'Alès</name>
      <address>
        <city>Alès</city>
        <zip>30100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dalila FERROUKHI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie ABADIE-LACOURTOISIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de cancérologie clinique - Institut Sainte-Catherine</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvie KIRSCHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servide d'Oncologie Médicale - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elsa KALBACHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut Bergonié</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne FLOQUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Onco-Hématologie - Hôpital Fleyriat</name>
      <address>
        <city>Bourg en Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hubert ORFEUVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Radiothérapie et Oncologie Médicale - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Véronique JESTIN-LE TALLEC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Uro-Gynécologie - Centre François Baclesse</name>
      <address>
        <city>Caen Cedex 5</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florence JOLY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Centre Hospitalier de Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabelle CAUVIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain ZANNETTI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servide d'Oncologie Médicale - Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie-Ange MOURET-REYNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Centre Hospitalier Alpes Leman</name>
      <address>
        <city>Contamines Sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carol René ALLIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Radiothérapie - Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuelle MALAURIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre d'Oncologie et de Radiothérapie du Parc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geneviève JOLIMOY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leïla BENGRINE LEFEVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Gériatrique - Centre Hospitalier Intercommunal des Alpes du Sud -Site de Gap</name>
      <address>
        <city>Gap</city>
        <zip>05000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier GUILLEM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Hôpital Michallon - CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hervé CURE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d''Hématologie Oncologie - Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay Cedex</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-François GEAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Jean Bernard - Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hugues BOURGEOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne et Oncologie Médicale - CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oana COJOCARASU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurence VENAT-BOUVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Service 2 B Nord - Centre Léon Bérard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier TREDAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie multidisciplinaire - Hôpital Nord</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marjorie BACIUCKHA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédérique ROUSSEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut Régional du Cancer Montpellier, Val d'Aurelle</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Véronique D'HONDT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins Cedex 02</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rémy LARGILLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chimiothérapie - Centre Catherine de Sienne</name>
      <address>
        <city>Nantes Cedex 2</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain LORTHOLARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Onco-Hématologie - Centre Antoine Lacassagne</name>
      <address>
        <city>Nice Cedex 2</city>
        <zip>06186</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe FOLLANA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Radiothérapie - Clinique de Valdegour</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacques CRETIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servicde d'Oncologie Médicale - Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orléans Cedex 02</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jérôme MEUNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Hôpital des Diaconesses</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Camille SERRATE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Hôpital Cochin</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jérôme ALEXANDRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emilie BOISSIER-BULTOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie - Groupe Hospitalier Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert SVERDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elise BAREL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service oncogériatrie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire FALANDRY, MD</last_name>
      <phone>4 78 86 15 80</phone>
      <phone_ext>+33</phone_ext>
      <email>claire.falandry@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Claire FALANDRY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre CARIO - Hôpital Privé des Côtes d'Armor</name>
      <address>
        <city>Plerin Sur Mer</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne-Claire HARDY-BESSARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servide d'Oncologie Médicale - Centre Hospitalier de la Région d'Annecy</name>
      <address>
        <city>Pringy Cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laetitia STEFANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servide de Radiothérapie et Oncologie Médicale - Centre Hospitalier Intercommunal de Cornouaille</name>
      <address>
        <city>Quimper Cedex</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Delphine MOLLON-GRANGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servide d'Oncologie Médicale - Institut Jean Godinot</name>
      <address>
        <city>Reims Cedex</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aude-Marie SAVOYE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier Yves le Foll</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corinne ALLEAUME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - ICO Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuelle BOURBOULOUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service d'Oncologie Médicale - Centre Hospitalier Broussais</name>
      <address>
        <city>Saint Malo</city>
        <zip>35403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hervé DESCLOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine interne et oncologie - Hôpital Inter Armées de Begin</name>
      <address>
        <city>Saint Mandé</city>
        <zip>94163</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Serge CREMADES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Clinique Mutualiste de l'Estuaire, Cité Sanitaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valérie DELECROIX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Radiothérapie - Centre Hospitalier Privé de Saint-Grégoire</name>
      <address>
        <city>Saint-Grégoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne MERCIER-BLAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Groupe Hospitalier Public du Sud de l'Oise - Site de Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth CAROLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Hospitalier de Sens</name>
      <address>
        <city>Sens</city>
        <zip>89108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laure CHAUVENET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thierry PETIT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie et Oncologie Gynécologique et Mammaire - Hôpitaux du Léman</name>
      <address>
        <city>Thonon les Bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco DEL PIANO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Loic MOUREY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre lès Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie-Christine KAMINSKY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Oncologique - Institut de Cancérologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine LHOMME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - CRO,IRCCS</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto SORIO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ulss 21 Legnago</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Filippo GRECO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Domenica LORUSSO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulls13 - Mirano</name>
      <address>
        <city>Mirano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grazia ARTIOLI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Nuovo di Sassuolo</name>
      <address>
        <city>Sassuolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sara PIRONDI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - Istituto di Candiolo</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giorgo VALABREGA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Per ROSENBERG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.arcagy.org</url>
  </link>
  <link>
    <url>http://www.esgo.org/engot/Pages/AboutENGOT.aspx</url>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2013</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Vulnerable</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

